|
Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. |
|
|
Consulting or Advisory Role - AstraZeneca; Baxalta/Shire; Baxter; Celgene; Lilly; Sanofi |
Research Funding - Celgene |
Travel, Accommodations, Expenses - Celgene |
Other Relationship - AstraZeneca; Celgene |
|
|
Consulting or Advisory Role - Aspen Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Pfizer |
Research Funding - Bayer (Inst); Leo Pharma (Inst) |
|
|
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I) |
Research Funding - AstraZeneca/MedImmune (Inst) |
|
|
Consulting or Advisory Role - Bayer |
Speakers' Bureau - Celgene; Eisai; Janssen Oncology |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Seagen (Inst); Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Roche |
Consulting or Advisory Role - Amgen; Baxter; Roche; SERVIER |
Travel, Accommodations, Expenses - Merck; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Celgene; Takeda |
|
|
Honoraria - Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Ipsen |
Speakers' Bureau - Taiho Pharmaceutical |
Research Funding - Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Taiho Pharmaceutical |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; BeiGene; Biocartis; Boehringer Ingelheim; Chugai Pharma; Foundation Medicine; Genentech; Genmab; HalioDx; Halozyme; Imugene; Inflection Biosciences; Ipsen; Kura Oncology; Lilly; Menarini; Merck Serono; Merrimack; Merus; Molecular Partners; MSD; Novartis; Peptomyc; Pfizer; Pharmacyclics; ProteoDesign; Rafael Pharmaceuticals; Roche; Roche; Sanofi; Seagen; Seagen; Servier; Symphogen; Taiho Pharmaceutical; VCN Biosciences |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Halozyme; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences |
Consulting or Advisory Role - Celgene; Ipsen; Merck; TriSalus Life Sciences |
Speakers' Bureau - Bayer; Celgene; Ipsen |
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); tyme (Inst); TYME (Inst) |
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals |
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Arno Therapeutics; AstraZeneca; Bayer Health; Celgene; Clovis Oncology; Cornerstone Pharmaceuticals; Eisai; EMD Serono; Five Prime Therapeutics; Genentech/Roche; ipsen; lsk biopharma; qed therapeutics; Seagen |
Research Funding - Bayer (Inst); BeiGene (Inst); boston biomedical (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); pfizer (Inst); Pharmacyclics (Inst); PsiOxus Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst) |
Travel, Accommodations, Expenses - Abbvie; Bayer; boston Biomedical; EMD Serono; Seagen |
Other Relationship - AstraZeneca |
|
|
Leadership - Cure Forward |
Honoraria - AstraZeneca; Celgene; Tusk Therapeutics |
Research Funding - Celgene |
|
|
Honoraria - Japan Pancreas Society; Oregon Health & Science University (OHSU) |
Consulting or Advisory Role - Abbvie; Advance Medical; Astellas Pharma; AstraZeneca; BIOPHARM; Bristol-Myers Squibb; Celgene (Inst); CPRIT; EcoR1 Capital; Eisai; FibroGen (Inst); Halozyme (Inst); Ignyta; Immunovia; Merck; Pharmacyclics; Pharmacyte Biotech; Tocagen |
Research Funding - Celgene (Inst); Halozyme (Inst) |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; BIOPHARM; Bristol-Myers Squibb; Celgene; CPRIT; Eisai; Halozyme; Pharmacyclics; Pharmacyte Biotech; Tocagen |